Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka Center for the Advancement of Higher Education, Faculty of Engineering, Kinki University, Hiroshima, Japan.
Hepatol Res. 2012 Dec;42(12):1157-67. doi: 10.1111/j.1872-034X.2012.01046.x. Epub 2012 Jun 3.
Some regions associated with sensitivity to interferon-α and ribavirin have been identified in the hepatitis C virus (HCV) genome, including amino acid 70 in the core region (core a.a. 70), a.a. 2209-2248 (interferon sensitivity-determining region, ISDR) and a.a. 2334-2379 (interferon and ribavirin resistance-determining region, IRRDR).
We examined changes in the sequences of these regions in 25 patients with chronic HCV genotype 1 infection who had not had sustained virological response (SVR) to interferon-α and ribavirin for 24-48 weeks and subsequently received retreatment for 48-72 weeks.
At baseline, the core a.a. 70 was mutant (resistant) type in seven patients. At the start of retreatment, the core a.a. 70 had changed from sensitive to resistant type in 2 patients, and SVR was not achieved by retreatment. The ISDR variations were resistant type (0-1 mutations) in 17 patients at baseline. After 2 weeks of treatment, amino acid change was found in two patients; in one, the substitutions returned to baseline status after treatment, and in the other, the substitution persisted. At the start of retreatment, ISDR sequences had changed from resistant to sensitive type in two patients and SVR was achieved and from sensitive to resistant type in three patients and SVR was not achieved. The IRRDR variations were resistant type (<6 mutations) in 19 patients at baseline and at the start of retreatment.
Sequences of the core region and ISDR sometimes change during anti-HCV therapy, potentially affecting the outcomes of retreatment.
已在丙型肝炎病毒(HCV)基因组中鉴定出与干扰素-α和利巴韦林敏感性相关的一些区域,包括核心区域的氨基酸 70(核心氨基酸 70)、氨基酸 2209-2248(干扰素敏感性决定区,ISDR)和氨基酸 2334-2379(干扰素和利巴韦林耐药决定区,IRRDR)。
我们检查了 25 例慢性 HCV 基因型 1 感染患者的这些区域序列变化,这些患者在接受干扰素-α和利巴韦林治疗 24-48 周后未获得持续病毒学应答(SVR),随后接受了 48-72 周的再治疗。
在基线时,7 例患者的核心氨基酸 70 为突变(耐药)型。在开始再治疗时,2 例患者的核心氨基酸 70 由敏感型变为耐药型,且再治疗未获得 SVR。17 例患者在基线时 ISDR 变异为耐药型(0-1 突变)。在治疗 2 周后,2 例患者发现氨基酸发生改变;在其中 1 例,治疗后替代物恢复到基线状态,而在另 1 例,替代物持续存在。在开始再治疗时,2 例患者的 ISDR 序列由耐药型变为敏感型,获得了 SVR,3 例患者由敏感型变为耐药型,未获得 SVR。19 例患者在基线和再治疗开始时的 IRRDR 变异为耐药型(<6 个突变)。
在抗 HCV 治疗期间,核心区域和 ISDR 的序列有时会发生变化,这可能会影响再治疗的结果。